Clinical Trial Update: Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating romiplostim (AMG531) in patients with aplastic anemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Aplastic Anemia | Phase 2, Phase 3 | Status: COMPLETED